AI analysis finds younger AFib patients benefit from MRI-guided ablation treatments

Younger atrial fibrillation (AFib) patients under 58 years old are most likely to benefit from more personalized, MRI-guided ablation treatments to correct irregular heart rhythms, according to a new artificial intelligence-guided analysis of results from the DECAAF II trial, one of the largest global studies of treatments for heart arrhythmias.

Read the full article here

Related Articles